ArticleCureus2026
Classification of Benign Hematogones and B-cell Acute Lymphoblastic Leukemia in Peripheral Blood Smear Images Using Artificial Intelligence.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
B-cell acute lymphoblastic leukemia (ALL) is a hematologic malignancy characterized by the abnormal proliferation of immature B-lineage lymphoblasts. Automated analysis of peripheral blood smear images may improve the speed and consistency of cell classification while supporting specialist interpretation. In this study, a cloud-based artificial intelligence image classification model was developed to differentiate benign hematogones from early pre-B, pre-B, and pro-B ALL categories. The model was trained and evaluated using 3,208 microscopic images from a publicly available dataset. Images were divided into training, validation, and testing subsets containing 2,568, 320, and 320 images, respectively, and model development was performed using Google Cloud AutoML (Google LLC, California, US). Performance was evaluated using average precision, precision, recall, precision-recall analysis, confidence-threshold evaluation, and a multiclass confusion matrix. At a confidence threshold of 0.50, the model achieved an average precision of 1.00, a precision of 100%, and recall of 99.4%. Class-specific correct classification rates were 100% for benign hematogones, early pre-B ALL, and pro-B ALL, and 98% for pre-B ALL, with the remaining pre-B images classified as early pre-B ALL. These findings demonstrate strong image-level performance within the internal testing dataset. External, multi-institutional, and patient-level validation is required before the model can be considered for clinical application.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.